159 related articles for article (PubMed ID: 11458813)
1. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Ibrahim NK; Valero V; Rahman Z; Theriault RL; Walters RS; Buzdar AU; Booser DJ; Holmes FA; Murray JL; Willey J; Bast R; Hortobagyi GN
Cancer Invest; 2001; 19(5):459-66. PubMed ID: 11458813
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Ibrahim NK; Rahman Z; Valero V; Willey J; Theriault RL; Buzdar AU; Murray JL; Bast R; Hortobagyi GN
Cancer; 1999 Oct; 86(7):1251-7. PubMed ID: 10506711
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer.
Ibrahim NK; Valero V; Theriault RL; Willey J; Walters RS; Buzdar AU; Booser DJ; Hortobagyi GN
Am J Clin Oncol; 2000 Apr; 23(2):117-21. PubMed ID: 10776969
[TBL] [Abstract][Full Text] [Related]
4. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
[TBL] [Abstract][Full Text] [Related]
5. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Ibrahim NK; Buzdar AU; Valero V; Dhingra K; Willey J; Hortobagyi GN
Cancer; 2001 Feb; 91(4):664-71. PubMed ID: 11241232
[TBL] [Abstract][Full Text] [Related]
8. Weekly schedule of vinorelbine in pretreated breast cancer patients.
Nisticò C; Garufi C; Milella M; Vaccaro A; D'Ottavio AM; Fabi A; Pace A; Bove L; Tropea F; Marsella A; Izzo F; D'Attino RM; Ferraresi V; De Marco S; Terzoli E
Breast Cancer Res Treat; 2000 Feb; 59(3):223-9. PubMed ID: 10832592
[TBL] [Abstract][Full Text] [Related]
9. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.
Jara-Sánchez C; Martín M; García-Sáenz JA; Barnada A; Fernández-Aramburo A; López-Vega JM; Pelegrí A; Alba E; Casado A;
Clin Breast Cancer; 2003 Feb; 3(6):399-404. PubMed ID: 12636884
[TBL] [Abstract][Full Text] [Related]
12. Infusional vinorelbine in relapsed or refractory lymphomas.
Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer.
Kosmas C; Agelaki S; Giannakakis T; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V
Oncology; 2002; 62(2):103-9. PubMed ID: 11914594
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G
Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.
Mariani G; Tagliabue P; Zucchinelli P; Brambilla C; Demicheli R; Villa E; Marchianò A; Valagussa P; Bonadonna G; Gianni L
Breast Cancer Res Treat; 2001 Dec; 70(3):163-9. PubMed ID: 11804180
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
[TBL] [Abstract][Full Text] [Related]
17. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
18. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
Campisi C; Fabi A; Papaldo P; Tomao S; Massidda B; Zappala A; Ionta MT; Cognetti F
Ann Oncol; 1998 May; 9(5):565-7. PubMed ID: 9653499
[TBL] [Abstract][Full Text] [Related]
20. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients.
Zambetti M; Demicheli R; De Candis D; Antonelli G; Giacobone A; Terenziani M; Laffranchi A; Garbagnati F; Biasi S; Bonadonna G
Breast Cancer Res Treat; 1997 Jul; 44(3):255-60. PubMed ID: 9266105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
